标题
Targeted therapies in colorectal cancer—an integrative view by PPPM
作者
关键词
Clinical decision-making process, Molecularly targeted treatment, Therapy response, Prediction, Therapy monitoring, Anti-EGFR, Anti-VEGF, Monoclonal antibody therapy, CRC management, Integrative medical approach
出版物
EPMA Journal
Volume 4, Issue 1, Pages -
出版商
Springer Nature
发表日期
2013-01-29
DOI
10.1186/1878-5085-4-3
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: Analysis of phase III studies.
- (2017) C. Bernaards et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI).
- (2017) E. Mrozek et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV).
- (2017) H. Hurwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Intra-tumoral Heterogeneity ofKRASandBRAFMutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing
- (2015) Susan D. Richman et al. Analytical Cellular Pathology
- Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients
- (2012) A Abajo et al. BRITISH JOURNAL OF CANCER
- Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection
- (2012) A Dewdney et al. BRITISH JOURNAL OF CANCER
- PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
- (2012) Arjun Sood et al. Clinical Colorectal Cancer
- Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: Results from a large treatment observational cohort study
- (2012) Fairooz F. Kabbinavar et al. EUROPEAN JOURNAL OF CANCER
- Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum
- (2012) Mai Yamauchi et al. GUT
- Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Stu
- (2012) Sebastian Stintzing et al. INTERNATIONAL JOURNAL OF CANCER
- Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer
- (2012) Natsuko Hori et al. International Journal of Clinical Oncology
- Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer
- (2012) Mariangela Manzoni et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes
- (2012) David J McBride et al. JOURNAL OF PATHOLOGY
- Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study
- (2012) Paola Ulivi et al. Journal of Translational Medicine
- NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy
- (2012) Fiona Rinaldi et al. LANCET ONCOLOGY
- VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
- (2012) Diether Lambrechts et al. LANCET ONCOLOGY
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial
- (2012) Zhong-Zhen Guan et al. Chinese Journal of Cancer
- Methods for analysis of the cancer microenvironment and their potential for disease prediction, monitoring and personalized treatments
- (2012) Carl-Magnus Clausson et al. EPMA Journal
- Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab †
- (2011) D. Malka et al. ANNALS OF ONCOLOGY
- Molecular Genetics of Colorectal Cancer
- (2011) Eric R. Fearon Annual Review of Pathology-Mechanisms of Disease
- Epidermal Growth Factor Receptor Pathway Mutations and Colorectal Cancer Therapy
- (2011) Allie H Grossmann et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Bevacizumab-Induced Hypertension
- (2011) Kostas N. Syrigos et al. BIODRUGS
- Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer
- (2011) Laetitia Dahan et al. BMC CANCER
- DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6
- (2011) J P B O'Connor et al. BRITISH JOURNAL OF CANCER
- EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer
- (2011) A Ålgars et al. BRITISH JOURNAL OF CANCER
- Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab
- (2011) Satoshi Matsusaka et al. CANCER
- Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer
- (2011) Fotios Loupakis et al. CANCER
- Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis
- (2011) Claire L. Vale et al. CANCER TREATMENT REVIEWS
- KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective
- (2011) P. R. Blank et al. CLINICAL CANCER RESEARCH
- Safety and Efficacy of Panitumumab Therapy After Progression With Cetuximab: Experience at Two Institutions
- (2011) Muhammad Wasif Saif et al. Clinical Colorectal Cancer
- The Efficacy and Safety of Panitumumab Administered Concomitantly With FOLFIRI or Irinotecan in Second-Line Therapy for Metastatic Colorectal Cancer: The Secondary Analysis From STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS Status
- (2011) Edith P. Mitchell et al. Clinical Colorectal Cancer
- The Continuation of Bevacizumab Following Disease Progression in Patients with Metastatic Colorectal Cancer Offers a Survival Benefit
- (2011) Georgios F. Samelis et al. HEPATO-GASTROENTEROLOGY
- Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany
- (2011) Arthi Vijayaraghavan et al. INTERNATIONAL JOURNAL OF CANCER
- Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy
- (2011) Satu Oltedal et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status
- (2011) Myoung Joo Kang et al. INVESTIGATIONAL NEW DRUGS
- Genetics, Cytogenetics, and Epigenetics of Colorectal Cancer
- (2011) Lucia Migliore et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
- (2011) Hiromichi Ebi et al. JOURNAL OF CLINICAL INVESTIGATION
- Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features
- (2011) Inti Zlobec et al. JOURNAL OF PATHOLOGY
- Growing tumor vessels: More than one way to skin a cat – Implications for angiogenesis targeted cancer therapies
- (2011) Rodrigo Leite de Oliveira et al. MOLECULAR ASPECTS OF MEDICINE
- Activation of the PIK3CA/AKT Pathway Suppresses Senescence Induced by an Activated RAS Oncogene to Promote Tumorigenesis
- (2011) Alyssa L. Kennedy et al. MOLECULAR CELL
- Bevacizumab in Clinical Practice: Prescribing Appropriateness Relative to National Indications and Safety
- (2011) M. Bonifazi et al. ONCOLOGIST
- Management of Skin Toxicity Associated with Cetuximab Treatment in Combination with Chemotherapy or Radiotherapy
- (2011) C. Pinto et al. ONCOLOGIST
- Morphological and molecular heterogeneity in colorectal neoplasms with K-RAS mutation. A report of two cases
- (2011) Hans Bösmüller et al. PATHOLOGY RESEARCH AND PRACTICE
- Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab
- (2011) A K Koutras et al. PHARMACOGENOMICS JOURNAL
- Molecular morphometric analysis shows relative intra-tumoural homogeneity for KRAS mutations in colorectal cancer
- (2011) Liora Farber et al. VIRCHOWS ARCHIV
- High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
- (2011) Nikhil Wagle et al. Cancer Discovery
- Microsatellite instability in the management of colorectal cancer
- (2011) Maria S Pino et al. Expert Review of Gastroenterology & Hepatology
- Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients
- (2010) M. Ronzoni et al. ANNALS OF ONCOLOGY
- The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-line chemotherapy and bevacizumab
- (2010) L. H. J. Simkens et al. ANNALS OF ONCOLOGY
- Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer
- (2010) Satoshi Matsusaka et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
- (2010) M. Janakiraman et al. CANCER RESEARCH
- Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
- (2010) S. E. Baldus et al. CLINICAL CANCER RESEARCH
- Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer
- (2010) Jan Pander et al. EUROPEAN JOURNAL OF CANCER
- Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab
- (2010) Jolien Tol et al. EUROPEAN JOURNAL OF CANCER
- Estimates of cancer incidence and mortality in Europe in 2008
- (2010) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools?
- (2010) Martin Zweifel et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 5-Fluorouracil Adjuvant Chemotherapy Does Not Increase Survival in Patients With CpG Island Methylator Phenotype Colorectal Cancer
- (2010) Rodrigo Jover et al. GASTROENTEROLOGY
- Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer
- (2010) Geraldine Perkins et al. INTERNATIONAL JOURNAL OF CANCER
- Unerwünschte dermatologische Wirkungen bei therapeutischer Inhibition des VEGF-Signalweges
- (2010) Gottfried Wozel et al. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
- Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599
- (2010) Suzanne E. Dahlberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Characteristics of recurrence after curative resection for T1 colorectal cancer: Japanese multicenter study
- (2010) Hirotoshi Kobayashi et al. JOURNAL OF GASTROENTEROLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Biomarkers to predict the clinical efficacy of bevacizumab in cancer
- (2010) Adrian M Jubb et al. LANCET ONCOLOGY
- BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis
- (2010) Chen Mao et al. MOLECULAR BIOLOGY REPORTS
- Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer
- (2010) D. G. Duda et al. ONCOLOGIST
- “First do no harm” and the importance of prediction in oncology
- (2010) Dainius Characiejus et al. EPMA Journal
- Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma
- (2009) P. Bono et al. ANNALS OF ONCOLOGY
- The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer
- (2009) K. -L. Garm Spindler et al. ANNALS OF ONCOLOGY
- Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
- (2009) J Souglakos et al. BRITISH JOURNAL OF CANCER
- PTEN status in advanced colorectal cancer treated with cetuximab
- (2009) F V Negri et al. BRITISH JOURNAL OF CANCER
- Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity andKRASstatus in patients receiving panitumumab monotherapy
- (2009) Marc Peeters et al. CANCER
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
- (2009) A. Sartore-Bianchi et al. CANCER RESEARCH
- PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer
- (2009) H. Prenen et al. CLINICAL CANCER RESEARCH
- Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function
- (2009) Wolfgang Lieb et al. EUROPEAN HEART JOURNAL
- PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer
- (2009) Fotios Loupakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
- (2009) Pierre Laurent-Puig et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
- (2009) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS Mutation
- (2009) Wilbur A. Franklin et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
- (2009) Andrew X Zhu et al. LANCET ONCOLOGY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
- (2009) Andrea Sartore-Bianchi et al. PLoS One
- Skin toxicities associated with epidermal growth factor receptor inhibitors
- (2009) Tianhong Li et al. Targeted Oncology
- PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
- (2008) F. Perrone et al. ANNALS OF ONCOLOGY
- Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
- (2008) M. Scartozzi et al. ANNALS OF ONCOLOGY
- Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon Cancer
- (2008) A. J. French et al. CLINICAL CANCER RESEARCH
- Correlation Between Rash and a Positive Drug Response Associated with Bevacizumab in a Patient with Advanced Colorectal Cancer
- (2008) M. Wasif Saif et al. Clinical Colorectal Cancer
- Implications of EGFR PharmDx™ Kit for cetuximab eligibility
- (2008) Christian Ensinger et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
- (2008) Bryan P. Schneider et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacogenetic Profiling for Cetuximab Plus Irinotecan Therapy in Patients With Refractory Advanced Colorectal Cancer
- (2008) Francesco Graziano et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Helical domain and kinase domain mutations in p110 of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
- (2008) L. Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started